Actavis + Allergan

Allergan Strengthens Med Derm & Aesthetic Portfolio with Acquisition

We are pleased to announce the completion of our acquisition of Anterios Inc., a privately-held biopharmaceutical company focused on developing topical botulinum toxin-based prescription products for medical dermatology and aesthetic medicine. This acquisition demonstrates Allergan’s ongoing commitment to the advancement of treatments in the medical dermatology and aesthetics space and is a prime example of Allergan’s Open Science R&D approach. We will seek to maximize the potential of Anterios’ platform technology NDS™ that enables local, targeted delivery of botulinum toxin across the skin without injections. Additionally, Allergan has acquired the rights to Anterios’ Phase 2 program ANT-1207, a botulinum toxin topical lotion, for the potential treatment of hyperhidrosis, acne, and crow’s feet lines.

The addition of a topical botulinum product will allow us to have the most comprehensive medical dermatology and aesthetic offering in the industry. We see ANT-1207 as a complementary product candidate to our existing portfolio, further strengthening Allergan’s neurotoxin pipeline and presence in some of the fastest growing segments in the aesthetics space—injectables, contouring and skin care. By offering alternative topical treatment options, we are expanding our market to reach a wider range of patients and physicians alike, who may be seeking an alternative needle-free option.
With the ANT-1207 programs currently in early-stage clinical studies, we will be able to leverage more than 25 years of botulinum expertise to fully shape the development process from the beginning and optimize the potential commercialization of this innovative product. We will be actively exploring what future indications should be pursued.
With your partnership, I am excited about the potential impact NDS™ and ANT-1207 may bring to you, your patients and the medical dermatology and aesthetic community. Most importantly, I want to thank you for your continued support of Allergan throughout a year of significant and exciting changes. We look forward to continuing to support you and your patients in 2016 and beyond.

Philippe Schaison
President & EVP, Allergan Medical